Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Nuvig cuts its CIDP trial, Cerevance's Parkinson's drug hits in Phase 3, plus RevMed, Tang's $75M SPAC, ViiV and AmyriAD news ...
The World Health Organization on Wednesday recommended against GLP-1 drugs for children with obesity who are under 10 and ...
Caribou drops vispa-cel and CB-011, cuts staff and explores strategic alternatives after failing to fund its allogeneic CAR-T ...
PhRMA sued CMS over GLOBE, the Trump admin's Medicare Part B demo tying drug prices to overseas rates, calling it unlawful.
The court ruled that Merck infringed one of Halozyme's patents and granted an injunction that bars Merck from marketing subcutaneous Keytruda in Belgium, Denmark, France, Ireland, Italy, Sweden, ...
Matchpoint Therapeutics has put together a $150 million Series B to help get MPT-062 into human testing after a $60 million upfront deal with Novartis.
The Palo Alto, CA-based firm announced a $600 million fund dedicated to Asia, where it is opening offices in Shanghai and Hong Kong.
Bexorg wins $28.3M ARPA-H award to keep human donor brains alive up to 2 weeks for drug testing. Co-founded by Yale's Nenad Sestan and CEO Zvonimir Vrselja.
MimiVax's glioblastoma vaccine SurVaxM narrowly misses Ph2b OS goal but shows 4-month gain in patients 65 and under.
The Boston-area biotech hasn’t released any data over the last four weeks, but it still was able to pull off a stock sale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results